Ophthalmic Therapy Developer EIR Biopharma Sets IPO Price Range at $4-$5 Per Share, Aiming to Raise $17 Million

Stock News02-18

Ophthalmic disease therapy developer EIR Biopharma filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Tuesday. The company plans to issue 3.8 million shares at a price range of $4 to $5 per share, aiming to raise approximately $17 million. EIR Biopharma intends to list on the small-cap market segment of the New York Stock Exchange, though a trading symbol has not yet been selected. Headquartered in San Francisco, California, EIR Biopharma is an early-stage biopharmaceutical company focused on treatments for eye diseases. The company acquires preclinical drug candidates from academic institutions and advances them into clinical development, targeting areas with clearly defined unmet medical needs. Its pipeline includes EIR-0205, a small-molecule therapy under development for the treatment of dry age-related macular degeneration, designed to remove lipofuscin from retinal pigment epithelial cells. Another candidate, EIR-1003, is a peptide-mimetic agent intended to mimic ephrin ligands and promote retinal neuron regeneration following optic nerve injury. The company is conducting pre-investigational new drug application studies for both programs and plans to initiate human clinical trials starting in 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172839132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172839132","market":"hk","top_or_hot":-1,"title":"Ophthalmic Therapy Developer EIR Biopharma Sets IPO Price Range at $4-$5 Per Share, Aiming to Raise $17 Million","media":"Stock News","content":"<p>Ophthalmic disease therapy developer EIR Biopharma filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Tuesday. The company plans to issue 3.8 million shares at a price range of $4 to $5 per share, aiming to raise approximately $17 million. EIR Biopharma intends to list on the small-cap market segment of the New York Stock Exchange, though a trading symbol has not yet been selected. Headquartered in San Francisco, California, EIR Biopharma is an early-stage biopharmaceutical company focused on treatments for eye diseases. The company acquires preclinical drug candidates from academic institutions and advances them into clinical development, targeting areas with clearly defined unmet medical needs. Its pipeline includes EIR-0205, a small-molecule therapy under development for the treatment of dry age-related macular degeneration, designed to remove lipofuscin from retinal pigment epithelial cells. Another candidate, EIR-1003, is a peptide-mimetic agent intended to mimic ephrin ligands and promote retinal neuron regeneration following optic nerve injury. The company is conducting pre-investigational new drug application studies for both programs and plans to initiate human clinical trials starting in 2027.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ophthalmic Therapy Developer EIR Biopharma Sets IPO Price Range at $4-$5 Per Share, Aiming to Raise $17 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOphthalmic Therapy Developer EIR Biopharma Sets IPO Price Range at $4-$5 Per Share, Aiming to Raise $17 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-18 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ophthalmic disease therapy developer EIR Biopharma filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Tuesday. The company plans to issue 3.8 million shares at a price range of $4 to $5 per share, aiming to raise approximately $17 million. EIR Biopharma intends to list on the small-cap market segment of the New York Stock Exchange, though a trading symbol has not yet been selected. Headquartered in San Francisco, California, EIR Biopharma is an early-stage biopharmaceutical company focused on treatments for eye diseases. The company acquires preclinical drug candidates from academic institutions and advances them into clinical development, targeting areas with clearly defined unmet medical needs. Its pipeline includes EIR-0205, a small-molecule therapy under development for the treatment of dry age-related macular degeneration, designed to remove lipofuscin from retinal pigment epithelial cells. Another candidate, EIR-1003, is a peptide-mimetic agent intended to mimic ephrin ligands and promote retinal neuron regeneration following optic nerve injury. The company is conducting pre-investigational new drug application studies for both programs and plans to initiate human clinical trials starting in 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO","symbol_name":"Renaissance IPO ETF","start_time":0,"source_url":"","article_id":"1172839132","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172839132","pubTimestamp":1771385537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Ophthalmic disease therapy developer EIR Biopharma filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Tuesday. The company plans to issue 3.8 million...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO":"Renaissance IPO ETF"},"translate_title":"眼科疗法开发商EIR Biopharma将IPO价格区间定为每股4-5美元，旨在融资1700万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO":1},"content_text":"Ophthalmic disease therapy developer EIR Biopharma filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission on Tuesday. The company plans to issue 3.8 million shares at a price range of $4 to $5 per share, aiming to raise approximately $17 million. EIR Biopharma intends to list on the small-cap market segment of the New York Stock Exchange, though a trading symbol has not yet been selected. Headquartered in San Francisco, California, EIR Biopharma is an early-stage biopharmaceutical company focused on treatments for eye diseases. The company acquires preclinical drug candidates from academic institutions and advances them into clinical development, targeting areas with clearly defined unmet medical needs. Its pipeline includes EIR-0205, a small-molecule therapy under development for the treatment of dry age-related macular degeneration, designed to remove lipofuscin from retinal pigment epithelial cells. Another candidate, EIR-1003, is a peptide-mimetic agent intended to mimic ephrin ligands and promote retinal neuron regeneration following optic nerve injury. The company is conducting pre-investigational new drug application studies for both programs and plans to initiate human clinical trials starting in 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172839132","isCrawlerRequest":true}